Immune Peptide Stack: Thymosin Alpha-1, Thymulin, KPV, and Larazotide Explained
Thymosin alpha-1 (synthetic form: thymalfasin, brand name Zadaxin outside the US), thymulin, KPV (Lys-Pro-Val, a tripeptide derived from alpha-melanocyte-stimulating hormone), and larazotide (AT-1001, an investigational octapeptide) are four structurally unrelated peptides that some compounding-based protocols group together as an "immune peptide stack." Each has a different proposed mechanism: T-cell maturation, thymic zinc-dependent signaling, cytokine dampening, and gut-barrier tightening, respectively.
None of the four is FDA-approved for general immune support in the United States. Thymalfasin carries a narrow orphan-drug designation for a specific pediatric immune deficiency; larazotide has been studied in celiac disease trials but has not received US marketing approval; thymulin and KPV have no FDA drug approval for any indication and exist in this context only as compounded preparations. No published trial has tested these four peptides in combination, so any claim that stacking them produces effects beyond what each does alone is an inference from separate single-agent literature, not a demonstrated result. That gap between plausible mechanism and demonstrated combination effect is the central thing a reader needs to understand before considering this protocol.
What each peptide is and what evidence actually supports it
The four agents are often described together because they act at conceptually different points in immune regulation. That conceptual complementarity is real. The strength of evidence behind each one is not equal, and readers should not treat "four mechanisms" as "four equally proven mechanisms."
| Peptide | What it is | Evidence type available | Regulatory status |
|---|---|---|---|
| Thymosin alpha-1 | 28-amino-acid peptide from prothymosin alpha; promotes T-cell maturation and dendritic-cell signaling | Multiple human randomized trials in hepatitis B/C, sepsis, and severe viral pneumonia (results vary by trial and population; effect sizes require verification against the primary papers before being quoted as fixed numbers) | Thymalfasin approved in dozens of countries for hepatitis and as an adjuvant in some cancers; FDA orphan designation only, not general approval |
| Thymulin | 9-amino-acid, zinc-dependent thymic epithelial hormone | Mechanistic and animal data are well described; direct human RCTs of thymulin as an isolated compound are sparse. Much of the "human evidence" cited in commercial materials is actually zinc-supplementation research used as an indirect proxy | No FDA approval; not a recognized drug product anywhere |
| KPV | 3-amino-acid fragment of alpha-MSH; MC1R/MC3R agonist that suppresses NF-kB-driven cytokines | Almost entirely rodent colitis models and in vitro work; systemic human data in the published literature are limited | No FDA approval; systemic use is off-label in every sense because there is no on-label use |
| Larazotide | 8-amino-acid zonulin antagonist; reduces intestinal tight-junction permeability | The most human trial data of the four, including phase 2 work in celiac disease; later-stage development outcomes and current trial status should be confirmed at clinicaltrials.gov before relying on any specific efficacy figure | Not FDA-approved; developed as an investigational drug, not currently marketed |
This is the honest evidence hierarchy: thymosin alpha-1 and larazotide have real human trial programs behind them (though the specific percentages sometimes quoted for these trials in compounding-pharmacy marketing material should be checked against the original publication before being repeated as fact). Thymulin and KPV rest mostly on animal and mechanistic work. Stacking a peptide with human RCT support alongside a peptide with only rodent data does not raise the rodent-data peptide to the same evidence tier.
Is there evidence that combining these four peptides works better than using one?
No published trial has tested thymosin alpha-1, thymulin, KPV, and larazotide together, in any combination, in humans. The rationale for stacking them, that they act on non-overlapping immune nodes, is a reasonable mechanistic hypothesis, not a tested clinical claim. There is also no published pharmacokinetic or pharmacodynamic interaction data for this combination. Any statement that the four peptides "work synergistically" or that combining them produces effects beyond what is seen with single agents is extrapolation and should be presented to patients as such.
What is established, what is plausible, and what is not established
Established: Zinc is required for thymulin's biological activity; zinc deficiency impairs thymulin-dependent T-cell maturation markers, a relationship documented in the endocrine-immunology literature. Larazotide has undergone human clinical trials in celiac disease. Thymalfasin has regulatory approval outside the US for specific viral and oncologic indications and has been studied in randomized trials for severe infection.
Plausible but unproven: That reducing gut permeability with larazotide meaningfully improves the efficacy of concurrently dosed thymosin alpha-1 or thymulin. That KPV's cytokine-braking effect, demonstrated mainly in rodent colitis models, translates to a comparable systemic anti-inflammatory effect in humans at the oral or subcutaneous doses used in compounding practice. That a four-peptide stack produces a durable, clinically meaningful change in general immune competence in an otherwise healthy adult.
Not established: That this specific four-peptide combination is safe or effective as a protocol distinct from its individual components. That any fixed dosing schedule is optimal, since no dose-finding studies exist for the combination. That the stack is appropriate for use outside a clinician-supervised, lab-monitored setting.
Safety signals by agent
Each peptide has a distinct risk profile, and combining them does not average those risks away.
Thymosin alpha-1 stimulates T-cell activity, which raises a theoretical concern for triggering or worsening autoimmune disease. Regulatory pharmacovigilance systems track adverse events for approved thymalfasin uses; a prescriber considering this agent for a patient with active lupus, rheumatoid arthritis, or MS should treat that history as a reason for specialist co-management rather than starting the peptide on the strength of a general immune-support rationale.
Thymulin at the doses used in compounded protocols has not been associated with serious adverse events in the available literature, but formulation stability is a real practical concern: zinc-thymulin complexes are reported to be temperature-sensitive, so storage and handling by the dispensing pharmacy matter.
KPV's mechanism, NF-kB inhibition, could in theory blunt an appropriate inflammatory response during an active infection. A reasonable clinical practice is to pause KPV during febrile illness. No formal drug-interaction studies exist for KPV combined with other anti-inflammatory agents.
Larazotide's published trial safety data describe an adverse-event profile similar to placebo, but tightening intestinal tight junctions could plausibly alter absorption of orally dosed narrow-therapeutic-index medications (for example warfarin, levothyroxine, or cyclosporine). This is a mechanistic concern that supports closer monitoring rather than a documented interaction.
Regulatory and sourcing reality (as of 2025)
None of these four peptides is an FDA-approved drug product for immune support. In the US they are available only through 503A compounding pharmacies operating on a patient-specific prescription, under FDA rules on human drug compounding. The FDA has placed increased scrutiny on bulk peptide substances used in compounding in recent years; prescribers and patients should confirm current status directly with the compounding pharmacy and, where relevant, the FDA's compounding guidance page, since bulk-substance eligibility lists change. Peptides purchased outside a licensed pharmacy chain of custody (research-chemical vendors, direct-to-consumer peptide sellers) carry unverified purity and identity risk; this is a general concern with unregulated peptide sourcing, not specific data about this particular stack, and should be treated as a sourcing-safety issue independent of the clinical questions above.
Clinician conversation and monitoring framework
This is a structure for the conversation between a patient and prescriber before, during, and after an immune peptide stack, and for deciding when to stop or escalate. It is a discussion tool, not a treatment protocol, and it does not replace individualized clinical judgment.
Before starting, confirm these with the prescriber:
- Which specific immune finding is being targeted (low CD4 count, elevated inflammatory markers, suspected gut permeability, thymic aging) and which single agent, if any, addresses that finding on its own before adding others
- Autoimmune disease history, current immunosuppressant or immune-stimulating medications, and any narrow-therapeutic-index drugs (warfarin, levothyroxine, cyclosporine) that could be affected if larazotide is included
- Baseline labs: CBC with differential, comprehensive metabolic panel, high-sensitivity CRP, ferritin, serum zinc, and CD4/CD8 ratio if T-cell status is the driving concern
- Sourcing: confirmation that the compounding pharmacy is appropriately licensed and can provide a certificate of analysis for each peptide
At the 4-week checkpoint, ask:
- Has CRP or the targeted inflammatory marker moved in the expected direction
- Are there any new autoimmune symptoms (new joint pain, rash, unexplained fatigue) that warrant pausing thymosin alpha-1
- If larazotide was added, have levels of any narrow-therapeutic-index medication been rechecked
At 8 to 12 weeks, ask:
- Has the CD4/CD8 ratio or other T-cell marker moved, and does that justify continuing, adjusting, or stopping thymosin alpha-1 or thymulin
- Has serum zinc normalized, and is thymulin still indicated if it has
- Is there a clinical reason to continue KPV or larazotide beyond the original target, or should they be tapered
Stop or escalate to urgent evaluation if:
- New or worsening autoimmune symptoms appear after starting thymosin alpha-1
- Fever or signs of active infection develop while on KPV (pause KPV and seek clinical evaluation of the infection itself)
- Unexplained changes in levels of a narrow-therapeutic-index medication occur after starting larazotide
- Any allergic reaction, significant injection-site reaction beyond mild erythema, or unexpected systemic symptom occurs after any injectable component
Where label guidance ends and individualized judgment begins: there is no FDA label for any of these four agents at these indications, so there is no dosing label to defer to. Reported dose ranges in the compounding and research literature are starting points for clinician judgment, not fixed prescriptions, and should be adjusted based on the patient's own labs and response rather than copied from a general reference.
Practical notes on typical compounded practice
Compounding literature and clinical practice commonly describe thymosin alpha-1 in the range of roughly 0.9 mg to 1.8 mg subcutaneously two to three times weekly, thymulin around 100 to 200 ng/kg, KPV around 500 to 1,000 mcg daily by mouth or subcutaneously, and larazotide around 0.5 mg to 1 mg by mouth with meals. These figures describe common practice patterns reported in the literature and by compounding pharmacies, not a validated dose-response protocol for this combination, and they are not a personal dosing recommendation. Actual dosing, sequencing, and duration should be set by the prescribing clinician based on the patient's labs, history, and response.
Frequently asked questions
Frequently asked questions
What is an immune peptide stack?
Is this stack FDA-approved?
Does thymulin need zinc to work?
Can KPV be taken during an active infection?
Is there proof that combining these four peptides works better than one alone?
What labs should be checked before and during this protocol?
Can thymosin alpha-1 worsen autoimmune disease?
Where can these peptides legally be obtained?
References
- U.S. Food and Drug Administration. Human drug compounding laws and policies. https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies
- U.S. Food and Drug Administration. Drug approvals and databases (accessdata). https://www.accessdata.fda.gov/scripts/cder/daf/
- Endocrine Society. Clinical practice guidelines (general reference; consult current guidance for peptide-specific recommendations). https://www.endocrine.org/clinical-practice-guidelines
Reported figures for outcomes such as mortality, cytokine reduction, and symptom-score changes vary between studies and have not been independently confirmed here, so they are described in general terms rather than with specific numbers. The development status of larazotide and the current FDA compounding eligibility of the peptides named should be confirmed independently, as these can change over time.